Chitosan was modified by coupling with linoleic acid through the 1-ethyl-3-(3-dimethylaminopropyl)- carbodiimide-mediated reaction to increase its amphipathicity for improved emulsification. The micelle formation of linoleic acid-modified chitosan in the 0.1 M acetic acid solution was enhanced by O/W emulsification with methylene chloride, an oil phase. The fluorescence spectra indicate that without emulsification the self-aggregation of LA-chitosan occurred at the concentration of 1.0 g/L or above, and with emulsification, self-aggregation was greatly enhanced followed by a stable micelle formation at 2.0 g/L. The addition of 1 M sodium chloride promoted the self-aggregation of LA-chitosan molecules both with and without emulsification. The micelles of LA-chitosan formed nanosize particles ranging from 200 to 600 nm. The LA-chitosan nanoparticles encapsulated the lipid soluble model compound, retinal acetate, with 50% efficiency.

Membranes were prepared from chitosan with different molecular weights by a casting method. The molecular affinity and permeability of the membranes for sodium chloride, glucose, tyrosine, and bovine serum protein were measured at 4

Different molecular weight (MW) chitosans (5.5

The captopril/Chitosan gelatin net-polymer microspheres ( Cap/CGNPMs) were prepared using Chitosan ( CS) and gelatin ( Gel) by the methods of emulsification. A cross linked reagent alone or in combination with microcrystalline cellulose (MCC) was added in the process of preparation of microspheres to eliminate dose dumping and burst phenomenon of microspheres for the improvement of the therapeutic efficiency and the decrease of the side effects of captopril ( Cap) . The results indicate that CapPCGNPMs have a spherical shape , smooth surface morphology and integral inside structure and no adhesive phenomena and good mobility , and the size distribution is mainly f rom 220 to 280 μm. Researches on the Cap release test in vitro demonstrate that Cap/CGNPMs are of the role of retarding release of Cap compared with Cap ordinary tablets ( COT) , embedding ratio ( ER) , drug loading ( DL) , and swelling ratio ( SR) , and release behaviors of CGNPMS are influenced by process conditions of preparation such as experimental material ratio ( EMR) , composition of cross linking reagents. Among these factors , the EMR (1/4) , CLR ( FOR + TPP) and 0. 75 % microcrystalline cellulose (MCC) added to the microspheres are the optimal scheme to the preparation of Cap/CGNPMs. The Cap/CGNPMs have a good characteristic of sustained release of drug , and the process of emulsification and cross-linking process is simple and stable. The CGNPMs is probable to be one of an ideal sustained release system for water-soluble drugs.

以羧甲基壳多糖(CMCH) 为材料，研制出一种用于动物细胞培养的新型微载体CX-2。对该微载体的色泽、干燥失重、比表面积、悬浮密度、直径、吸水量、溶胀度、粒度分布、表面结构、机械强度、稳定性等理化指标进行了测定，结果表明，CX-2 是一种性能良好的微载体。细胞学实验表明，BB 细胞能较好地黏着于CX22 微载体上，在24～72h 期间细胞生长增殖速度快，120h 时细胞已呈现多层次生长状态。再生后的CX-2 ，可继续用于BB细胞培养，效果无明显变化。结果初步表明，CX-2 为新型的、适于动物细胞大规模培养的、可再生利用的微载体。